A Multi-Center, Partially Blinded, Maximum Tolerated Multiple Dose Escalation, Phase 1 Clinical Trial to Evaluate the Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) With Advanced Hepatic Fibrosis

Trial Profile

A Multi-Center, Partially Blinded, Maximum Tolerated Multiple Dose Escalation, Phase 1 Clinical Trial to Evaluate the Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) With Advanced Hepatic Fibrosis

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2016

At a glance

  • Drugs GR MD 02 (Primary)
  • Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
  • Focus Adverse reactions; First in man
  • Sponsors Galectin Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Oct 2016 Results published in the Alimentary Pharmacology and Therapeutics
    • 07 Jan 2015 Status changed from recruiting to completed, according to a Galectin Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top